The Chicago Entrepreneur

Eli Lilly to pay $3.2 billion in cash to buy this biotech with an IBD treatment

Morphic’s stock rocketed Monday, after the biopharmaceutical company announced an agreement to be acquired by Eli Lilly in a cash deal valued at about $3.2 billion.

Previous post Devon Energy to pay $5 billion for unit of EnCap-backed Grayson Energy
Next post Corning’s stock soars 7% after company raises Q2 guidance to reflect AI bump